CD8A and cancer: On this note, ablation of the PGE2–EP2/EP4 signalling axis to enhance IL-2 responsiveness in adoptively transferred cancer-specific CD8+ T cells bears the promise to unleash their full potential to mount protective anticancer immunity not only in mice but also in cancer patient-derived TILs, as demonstrated in the accompanying paper37.